Products
Mirvaso brimonidine gel was approved in the EU in 2013 and in many countries in 2014.
Structure and properties
Brimonidine (C11H10BrN5, Mr = 292.1 g/mol) is present in the drug as brimonidine tartrate, a white to yellow powder that is soluble in water. It has a similar structure to clonidine and apraclonidine.
Effects
Brimonidine (ATC D11AX21) has vasoconstrictor properties. It is a selective antagonist at the alpha2-adrenoceptor. The effects are due to vasoconstriction in the skin.
Indications
For symptomatic treatment of facial erythema in rosacea.
Dosage
According to the SmPC. The gel is applied once daily (every 24 hours).
Contraindications
- Hypersensitivity
- Children under two years
- Concurrent treatment with an MAO inhibitor or with tri- or tetracyclic antidepressants that affect noradrenergic transmission
For complete precautions, see the drug label.
Interactions
Drug interactions with the following substances cannot be ruled out:
- MAO inhibitors
- Tri- or tetracyclic antidepressants, which affect noradrenergic transmission
- Central depressant drugs, alcohol
- Agents that may affect the metabolism and uptake of circulating amines.
- Agonists or antagonists at alpha-adrenoceptors.
- Antihypertensives, cardiac glycosides
Adverse effects
The most common possible adverse effects include skin redness, itching, skin burning, and flushing.